Singula Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Singula Bio is a UK-based, private biotech founded in 2019, originating from the University of Oxford. The company is developing a personalized cell therapy platform that identifies, expands, and reinfuses a patient's own tumor-specific T cells to target neoantigens in solid tumors. As a pre-clinical, pre-revenue entity, it aims to address the significant unmet need in solid tumor oncology by creating individualized therapies to prevent recurrence and improve survival.

OncologySolid TumorsOvarian Cancer

Technology Platform

Proprietary platform for the identification and ex vivo expansion of a patient's own neoantigen-specific T cells to create personalized autologous cell therapies for solid tumors.

Opportunities

The massive unmet need in solid tumor oncology, particularly in recurrent settings like ovarian cancer, presents a multi-billion dollar market.

A successful platform could be expanded across multiple solid tumor types, offering a scalable personalized therapy model in a rapidly growing cell therapy sector.

Risk Factors

High scientific risk associated with making cell therapies effective in the immunosuppressive solid tumor microenvironment.

As a seed-stage company, it faces significant funding and execution risk, and operates in a fiercely competitive neoantigen therapy landscape with larger, well-capitalized players.

Competitive Landscape

Singula Bio competes in the crowded and rapidly evolving field of neoantigen-targeted therapies, which includes companies developing personalized cancer vaccines, TCR-T cells, and other adoptive cell therapies. It faces competition from both large pharma and numerous biotech startups, all aiming to solve the challenge of solid tumor immunotherapy.

More companies in Cell & Gene Therapy →More companies in United Kingdom →